

ARV Therapies and Therapeutic Strategies

REPORTING ON CROI 2015

Comprehensive Expert Review and Discussion of Key Presentations

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy Combined Primary Results of Studies GS-US-292-0104 and GS-US-292-0111

David Wohl¹, Anton Pozniak², Melanie Thompson³, Edwin DeJesus⁴, Daniel Podzamcer⁵, Jean-Michel Molina⁶, Gordon Crofoot⁷, Christian Callebaut⁸, Hal Martin⁸, Scott McCallister⁸


¹University of North Carolina, Chapel Hill, NC; ²Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK; ³AIDS Research Consortium of Atlanta, Atlanta, GA; ⁴Orlando Immunology Center, Orlando, FL; ⁵Hospital Universitari de Bellvitge, Barcelona, Spain; ⁶Hôpital Saint Louis, Paris, France; ⁷Gordon Crofoot Research, Houston, TX; ⁸Gilead Sciences, Foster City, CA

Abstract 113LB

TAF vs TDF: Study Design



TAF vs TDF: Virologic Results




E/C/F/TAF was non-inferior to E/C/F/TDF at Week 48 in each study

- 93% E/C/F/TAF vs 92% E/C/F/TDF (Study 104)
- 92% E/C/F/TAF vs 89% E/C/F/TDF (Study 111)

High and similar response rates, irrespective of age, sex, race, HIV-1 RNA, and CD4 cell count


Wohl D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 113LB.

Efficacy by Baseline HIV-1 RNA and CD4 Count Studies 104 and 111: Week 48 Combined Analysis




Wohl D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 113LB.

Efficacy in Select Subgroups Studies 104 and 111: Week 48 Combined Analysis



Wohl D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 113LB.

Median Change from Baseline in CD4 Count Studies 104 and 111: Week 48 Combined Analysis



Wohl D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 113LB.

TAF vs TDF: Resistance Outcome

	E/C/F/TAF n=866	E/C/F/TDF n=867
Patients analyzed for resistance, n (%)	16 (1.8)	19 (2.2)
Primary Genotypic Resistance		
Any, n (%)	7 (0.8)	5 (0.6)
Study 104, n	3	3
Study 111, n	4	2
Any	7	5
NRTI Resistance, n		
M184V/I	6	3
M184V/I + K65R	1	2
Any	5	3
T66A	1	0
E92Q	2	1
INSTI Resistance, n		
Q148R	0	1
Q148R + T66I/A	1	0
Q148R + E92Q	0	1
N155H	1	0

Wohl D, et al. 22nd CROI; Seattle, WA; February 23-26, 2015. Abst. 113LB.